drugset / Trial / NCT02503904

Tumescent Antibiotic Delivery for Prevention of Surgical Site Infection

NCT02503904

Phase 2/3 Unknown 400 enrolled Klein, Jeffrey A., M.D.
RandomizedParallel-groupOpen-labelPrevention

Summary

The principal aim of the present research is to compare two methods of antibiotic delivery: concomitant tumescent antibiotic delivery (TAD) and intravenous antibiotic delivery (IVAD) versus IVAD alone, (TAD+IVAD vs IVAD), with respect to the prevention of surgical site infections (SSI). The investigators hypothesize that TAD+IVAD will significantly reduce the incidence of SSI compared to IVAD. TAD is the subcutaneous infiltration of a dilute solution of antibiotic(s) in a solution of tumescent local anesthesia (TLA). TLA consists of a dilute solution of lidocaine (1gm/L), epinephrine (1mg/L) and sodium bicarbonate (10mEq/L) in 0.9% physiologic saline. A secondary aim of this study is to compare TAD+IVAD vs IVAD with respect to the prevention of post-operative venous thromboembolism (VTE).

Timeline

Start
2015-10
Primary completion
2019-06
Completion
2019-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cefazolin Small molecule Subcutaneous
Comparator Epinephrine Other / unclassified 0.001 mg/ml Subcutaneous
Comparator Lidocaine Other / unclassified 1 mg/ml Subcutaneous
Comparator Metronidazole Small molecule Subcutaneous
Comparator sodium bicarbonate Diagnostic / imaging agent 0.01 meq Subcutaneous